A potent, third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. MW: 554.66. Purity ≥98% by HPLC